An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer

This study tests iruplinalkib, a targeted drug that blocks an abnormal protein called ROS1, in patients with non-small cell lung cancer (NSCLC) that carries a specific ROS1 gene change. ROS1-positive lung cancers are driven by this gene alteration, and targeted drugs can block it. **You may be eligible if...** - You are 18 or older - You have been diagnosed with stage III (unresectable) or stage IV NSCLC with a confirmed ROS1-positive gene change - Your cancer has at least one measurable tumor - You are in good general health (ECOG performance status 0–2) - You are able to swallow pills - Brain metastases are allowed if they are asymptomatic or have been stable for at least 4 weeks after treatment **You may NOT be eligible if...** - You are currently in another clinical trial using a different investigational drug - You have mixed small cell and non-small cell lung cancer - You have severe heart problems or a significant history of cardiovascular/cerebrovascular disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.